Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Tenofovir Stories

2010-11-16 13:27:00

NEW ORLEANS, and RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2010 /PRNewswire/ -- Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company's lipid-conjugated drugs, CMX001 and CMX157, are not substrates for the human Organic Anion Transporters (hOATs) and thus have significantly reduced potential to cause nephrotoxicity via this mechanism. These data, presented at the International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC...

2010-10-27 07:00:00

BURLINGTON, Mass., Oct. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the HIV drug market will experience an average annual increase of 3.1 percent from 2009 to 2014 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Thereafter, market growth will slow to 2.2 percent annually from 2014 through 2019, owing largely to the generic erosion of several key...

2010-09-22 09:49:22

(Ivanhoe Newswire) "“ Higher clinical drop-out rates among women are a concern when testing for effectiveness of HIV treatments. This new landmark study showed that after recruiting and keeping women in the study, there are no major gender differences in the effectiveness of treating HIV. Previously, women were dropping out of the GRACE study (Gender, Race, and Clinical Experience) like flies, for reasons that weren't due to the ineffectiveness of the drug. This showed that there...

2010-09-21 11:33:45

Higher clinical trial drop-out rates among women remain a concern A new landmark study, which demonstrated it is possible to recruit large numbers of women into a clinical trial evaluating treatments for HIV infection, found no significant gender-based differences in response to the anti-HIV drugs darunavir and ritonavir "” at least among those who remained in the trial to the end. However, women dropped out of the GRACE (Gender, Race and Clinical Experience) study at higher rates than...

2010-09-03 12:14:00

NEW YORK, Sept. 3 /PRNewswire-USNewswire/ -- AVAC today issues a call to action to donors, policy-makers, researchers and advocates to ensure that critical follow-up studies to the landmark CAPRISA 004 microbicide trial receive the economic and political support needed to move forward as quickly as possible. The call comes as a group of microbicide and public health experts have agreed upon a plan for further studies, which are expected to cost $100 million over three years, of which only...

2010-07-28 07:35:00

RESEARCH TRIANGLE PARK, N.C., July 28 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil...

2010-07-26 07:30:00

TITUSVILLE, N.J., July 26 /PRNewswire/ -- Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals. The...

2010-07-22 07:30:00

VIENNA, July 22 /PRNewswire/ -- Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults. These global trials, known as ECHO and THRIVE, reached...

2010-07-19 15:31:00

CAPRISA 004 trial shows moderate protection against transmission of virus JOHANNESBURG and WASHINGTON, July 19 /PRNewswire-USNewswire/ -- Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria. The CAPRISA 004 trial, which tested the safety and effectiveness of 1% tenofovir gel among nearly 900 women at two sites in South Africa, found that using the gel before and after sex provided...

2010-07-19 15:10:00

WASHINGTON, July 19 /PRNewswire-USNewswire/ -- USAID Administrator Rajiv Shah released the following statement on today's historic CAPRISA 004 trial results: (Logo: http://photos.prnewswire.com/prnh/20091022/USAIDLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20091022/USAIDLOGO) USAID is proud to be the major funder of the first-ever proof of concept that a microbicide can effectively and safely reduce the transmission of HIV from men to vulnerable women. An achievement of this...